Hemodialysis Treatment Articles & Analysis
10 news found
- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patients - - Approval is Based on Positive Efficacy and Safety Results of the ILLUMINATE-C Phase 3 Study of OXLUMO in PH1 Patients with Severe Renal Impairment, Including Those on Hemodialysis - CAMBRIDGE, ...
£1 million grant will support first-in-human clinical trials of H-Guard Invizius Limited ("Invizius"), a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has been awarded a £1 million grant to bring H-Guard, its proprietary priming solution, designed to reduce the life-threatening inflammatory effects of ...
” Thoracic central venous obstruction occurs in roughly 40% of patients where hemodialysis is performed via a central venous catheter.[1] While permanent arteriovenous fistulas are the preferred form of vascular access for hemodialysis patients, central venous catheters continue to serve as an important bridge to securing long-term access for life-saving ...
£5.3 million financing to complete First-in-Man safety study Led by Mercia, Downing Ventures, Old College Capital, Scottish Enterprise and Solvay Ventures; welcomes new investors Calculus Capital and Dr Jonathan Milner Invizius, a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has closed Series A financing of ...
The Ellipsys® Vascular Access System enables patients with kidney failure to start dialysis treatment sooner with fewer procedures, complications and interventions compared to surgery, according to several leading physicians who spoke at the recent meeting of the American Society of Diagnostic and Interventional Nephrology (ASDIN). ...
The recently FDA-approved Ellipsys System is a minimally-invasive, single catheter-based system designed for ESRD patients requiring hemodialysis. Pioneered in Arizona by Drs. Cooper and Waheed, the new procedure and technology bring patients a unique non-surgical option for AVF creation, a procedure that had previously not changed in over 50 years. ...
In the United States, more than 470,000 patients with kidney failure rely on thrice-weekly hemodialysis treatment to survive. Maintaining a reliable vascular access site for these patients is challenging, and options for such access are limited. ...
On March 12, the CFDA released about approval to release the hemodialysis and related water treatment, etc. The announcement of 90 standards for medical devices industry. ...
Healionics’ STARport HD, a novel preclinical stage implantable device that allows needle-free bloodstream access for hemodialysis treatment, has been selected by the American Society of Nephrology (ASN) to be featured at the ASN exhibit booth at Kidney Week 2016 as one of several new technologies portraying the future of kidney disease ...
In the United States, More than 400,000 End Stage Renal Disease (ESRD) patients - those with irreversible kidney failure – rely on thrice-weekly hemodialysis treatment to survive. Maintenance of a reliable vascular access site for these patients is challenging and options for access methods are limited. ...